Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
28.71
-0.34 (-1.17%)
At close: Apr 2, 2026, 4:00 PM EDT
28.50
-0.21 (-0.73%)
After-hours: Apr 2, 2026, 5:33 PM EDT
Maze Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
141
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 167.50M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMAZE News
- 6 days ago - Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop - Seeking Alpha
- 7 days ago - MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 8 days ago - Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
- 8 days ago - Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - GlobeNewsWire
- 8 days ago - Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 5 weeks ago - Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Maze Therapeutics: An Innovative, Nature-Driven Platform - Seeking Alpha